Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Accumulated Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Accumulated Expenses for 7 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 47.48% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.3 million through Dec 2025, down 47.48% year-over-year, with the annual reading at $18.3 million for FY2025, 47.48% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $18.3 million at Kymera Therapeutics, up from $11.7 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $34.9 million in Q4 2024, with the low at $1.3 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $17.7 million, with a median of $20.9 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses soared 687.22% in 2021, then plummeted 67.95% in 2022.
  • Over 5 years, Accumulated Expenses stood at $23.0 million in 2021, then rose by 19.72% to $27.5 million in 2022, then rose by 23.13% to $33.9 million in 2023, then rose by 2.96% to $34.9 million in 2024, then plummeted by 47.48% to $18.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $18.3 million, $11.7 million, and $28.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.